Kinetic modeling of 68 Ga-PSMA-11 and validation of simplified methods for quantification in primary prostate cancer patients.
| Autor: | Ringheim A; Hospital Israelita Albert Einstein, Avenida Albert Einstein 627/701, Morumbi, Sao Paulo, SP, CEP 05652-900, Brazil. anna.m.ringheim@gmail.com., Campos Neto GC; Hospital Israelita Albert Einstein, Avenida Albert Einstein 627/701, Morumbi, Sao Paulo, SP, CEP 05652-900, Brazil., Anazodo U; Lawson Health Research Institute, St Joseph's Health Care, 268 Grosvenor Street, London, Ontario, N6A 4V2, Canada.; Department of Medical Biophysics, Western University, 1151 Richmond Street N, London, Ontario, N6A 5C1, Canada., Cui L; Division of Biomedical Engineering, University of Saskatchewan, 57 Campus Drive, Saskatoon, Saskatchewan, SK, S7N 5A9, Canada., da Cunha ML; Hospital Israelita Albert Einstein, Avenida Albert Einstein 627/701, Morumbi, Sao Paulo, SP, CEP 05652-900, Brazil., Vitor T; Hospital Israelita Albert Einstein, Avenida Albert Einstein 627/701, Morumbi, Sao Paulo, SP, CEP 05652-900, Brazil., Martins KM; Hospital Israelita Albert Einstein, Avenida Albert Einstein 627/701, Morumbi, Sao Paulo, SP, CEP 05652-900, Brazil., Miranda ACC; Hospital Israelita Albert Einstein, Avenida Albert Einstein 627/701, Morumbi, Sao Paulo, SP, CEP 05652-900, Brazil., de Barboza MF; Hospital Israelita Albert Einstein, Avenida Albert Einstein 627/701, Morumbi, Sao Paulo, SP, CEP 05652-900, Brazil., Fuscaldi LL; Hospital Israelita Albert Einstein, Avenida Albert Einstein 627/701, Morumbi, Sao Paulo, SP, CEP 05652-900, Brazil., Lemos GC; Hospital Israelita Albert Einstein, Avenida Albert Einstein 627/701, Morumbi, Sao Paulo, SP, CEP 05652-900, Brazil., Colombo Junior JR; Hospital Israelita Albert Einstein, Avenida Albert Einstein 627/701, Morumbi, Sao Paulo, SP, CEP 05652-900, Brazil., Baroni RH; Hospital Israelita Albert Einstein, Avenida Albert Einstein 627/701, Morumbi, Sao Paulo, SP, CEP 05652-900, Brazil. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | EJNMMI research [EJNMMI Res] 2020 Feb 24; Vol. 10 (1), pp. 12. Date of Electronic Publication: 2020 Feb 24. |
| DOI: | 10.1186/s13550-020-0594-6 |
| Abstrakt: | Background: The positron emission tomography (PET) ligand 68 Ga-Glu-urea-Lys(Ahx)-HBED-CC ( 68 Ga-PSMA-11) targets the prostate-specific membrane antigen (PSMA), upregulated in prostate cancer cells. Although 68 Ga-PSMA-11 PET is widely used in research and clinical practice, full kinetic modeling has not yet been reported nor have simplified methods for quantification been validated. The aims of our study were to quantify 68 Ga-PSMA-11 uptake in primary prostate cancer patients using compartmental modeling with arterial blood sampling and to validate the use of standardized uptake values (SUV) and image-derived blood for quantification. Results: Fifteen patients with histologically proven primary prostate cancer underwent a 60-min dynamic 68 Ga-PSMA-11 PET scan of the pelvis with axial T1 Dixon, T2, and diffusion-weighted magnetic resonance (MR) images acquired simultaneously. Time-activity curves were derived from volumes of interest in lesions, normal prostate, and muscle, and mean SUV calculated. In total, 18 positive lesions were identified on both PET and MR. Arterial blood activity was measured by automatic arterial blood sampling and manual blood samples were collected for plasma-to-blood ratio correction and for metabolite analysis. The analysis showed that 68 Ga-PSMA-11 was stable in vivo. Based on the Akaike information criterion, 68 Ga-PSMA-11 kinetics were best described by an irreversible two-tissue compartment model. The rate constants K Conclusions: 68 Ga-PSMA-11 kinetics can be described by an irreversible two-tissue compartment model. An MR-guided method for image-derived blood provides a non-invasive alternative to blood sampling for kinetic modeling studies. SUV showed strong correlation with K |
| Databáze: | MEDLINE |
| Externí odkaz: |
|